Khuri 3

INTRODUCTION:
The institution of cardiopulmonaiy bypass alters hemostasis and results in increased postoperative bleeding (1) . Platelet dysfunction and increased fibrinolysis are two mechanisms that are primarily responsible for the hemostatic dysfunction induced by car<üopulmönary~6ypass (1) . Although contact with the extracorporeal circuit results in platelet loss secondary to platelet activation, secretion, and degranulation, the resultant thrombocytopenia encountered in the majority of patients undergoing cardiopulmonary bypass is not severe enough to account for the platelet dysfunction observed in these patients, which is manifested by a marked prolongation of the postoperative bleeding time (2) . It was postulated that cardiopulmonary bypass induced platelet dysfunction by altering the platelet membrane receptors GP lb and GP Db/nia. A recent collaborative study from our institution demonstrated that the membrane receptors were intact in the platelet circulating during cardiopulmonary bypass (3) . It suggested that factors extrinsic to the platelet might be important determinants of the platelet dysfunction observed during and following cardiopulmonary bypass. Hypothermia, for example, has been clearly shown to prolong the bleeding time and to reduce the platelet production of thromboxane A2 in patients undergoing cardiopulmonary bypass (4) .' Heparin, which is universally used in patients undergoing cardiopulmonary bypass, is another extrinsic factor which may influence platelet function in these patients. Heparin has also been shown to have profibrinolytic activity (5) . Hence, heparin may contribute to the hemostatic abnormality of cardiopulmonary bypass not only by its inhibition of thrombin, but also by inducing platelet dysfunction and by promoting fibrinolysis. This investigation was carried out to elucidate the effect of the administration of heparin prior to the institution of cardiopulmonary bypass on platelet function and fibrinolytic activity in patients Khuri 4 undergoing cardiac surgery.
MATERIALS AND METHODS:
The patient population: This study was conducted in 55 patients (54 males, 1 female) undergoing cardiac surgery at the West Roxbury Veterans Affairs Medical Center. Themean age (± Standard Deviation) of the patients was 64±8.7 years. The operations performed included isolated coronary artery bypass grafting (CABG, n=38), isolated valve replacement (n=5), and valve replacement with CABG (n=12). AU patients signed consent forms approved by the institutional review board. No patient had a history suggestive of an underlying hemostatic disorder. Patients were not entered into the study if they had a history of aspirin, antiinflammatory, or fibrinolytic drug intake within one week prior to the operation. All patients were premedicated with droperidol and fentanyl citrate (Innovar) and diphenhydramine hydrochloride (Benadryl). Anesthesia was induced with fentanyl and lidocaine and maintained with fentanyl and halothane. After an initial heparin dose of 4 mg/kg, cardiopulmonary bypass was begun. A membrane oxygenator and a circuit primed with lactated Ringer's solution were used. Subsequent heparin dosages were determined according to the activated clotting time, which was maintained greater than 600 seconds. After discontinuation of cardiopulmonary bypass, heparin was neutralized with protamine sulfate given in a ratio of 0.5 mg of protamine to 1.0 mg of the initial heparin dose and 1.0 mg of protamine to 1.0 mg for the subsequent heparin dosages. Heparin reversal was also monitored by the measurement of the activated clotting time.
Blood samples and assays: After opening the chest and prior to cannulation for cardiopulmonary bypass, two arterial blood samples were obtained, one before and one five minutes after the administration of heparin. Blood was collected for the measurement of Khuri 5 hematocrit and platelet count employing a Coulter ZBI Counter (Counter Electronics, Hialeah, Fla.). vWF antigen concentration was measured with enzyme-linked immunosorbent assay (6).
VWF Multimer distribution was assessed by separating plasma proteins electrophoretically on a SDS=1% agarose gel using a continuous buffer (7) . vWF antigen was identified by Incubating the gel with 125 I-anti vWF antibody followed by autoradiography. Each sample was tested at least twice on separate gels to ensure reproducibility. Multimer distribution was assessed by visual inspection of the autoradiograph. Plasminogen and plasmin activity in plasma were measured employing the same substrate (2) . Measurements of t-PA were made using enzyme-linked immunosorbent assay (ELISA). Samples for measurement of fibrinogen were collected in 3.8% sodium citrate tubes, centrifuged at 1200g for 10 minutes. After neutralization with protamine, fibrinogen was measured using a Coag-a-Mate X2 photo optical instrument (General every 30 seconds was aspirated through a blunt needle into a tuberculin syringe coated with heparin (1000 U/ml) and containing 20 ul of ibuprofen for 1 ml of blood (1.9 mg/ml). Each template produced two skin incisions, and two templates were used at each period, one for measurement of the duplicate bleeding times and the recording of the mean value, and theother for collection of the shed blood from the skin incision. A volume of 0.6 ml of blood was collected from the bleeding time site for these measurements. The blood samples were kept on ice until they were centrifuged at 1650g (3000 rpm) in a Sorvall GLC-3 centrifuge (DuPont Company, Wilmington, DE.) for 10 minutes. The plasma was removed and frozen at -80 °C until assays for thromboxane B 2 levels were done. Assays were performed with thromboxane B 2 (iodine 125) radioimmunoassay kits (New England Nuclear Corp., Boston, MA)
Data analysis: The bleeding time was corrected for temperature applying the factor described by Valeri et al (9) . The plasma proteins were corrected for hemodilution as described previously (1) . Comparisons were made between-data obtained before and after the administration of heparin using the paired student t test. Statistical significance was set at Pi 0.05. Correlations were performed employing linear regression analysis. Analyses were done using SAS Statistical Software (SAS Institute Inc., Cary, NC). The mean values in the narrative and the tables are shown ± their standard deviation; in the figures, they are shown ± their standard error.
RESULTS
Skin temperature, hematocrit and platelet count:
The skin temperature at the site of the bleeding time determination drifted downward by an average of 1 °C ( Figure 1 ). This drift was ascribed to progressive cooling of the skin secondary to a low ambient temperature in the operating room and to the opening of the chest. In the 55 patients it averaged 29.7±1.3°C before Khuri 7 heparin and 28.7 + 1.7 C after heparin. This difference, though small, was highly significant (p=0.0004). seconds. In most of the patients, heparin was administered to achieve an ACT of more than 600 seconds. As a result, the ACT after the administration of the first dose of heparin ranged from 479 to 1000 seconds and averaged 870+168
seconds. Heparin concentration in the blood prior to heparinization was 0.22 + 0.11 Ill/ml. After the first dose, it ranged from 0.2 to 9.4 lU/ml and averaged 6.26 + 1.53 lU/ml. There was no correlation between the ACT and the blood heparin concentration (r=0.09) following the administration of the first dose of heparin.
Platelet Function: Platelet function parameters before and 5 minutes after heparin administration are shown in Table 1 . The bleeding time prior to heparin administration ranged from 3.5 to 10.5 minutes and averaged 6.3 minutes.
Following the administration of heparin, the bleeding time increased in all but two patients ( Figure 2) ; it averaged 12.6 minutes. This was a marked and significant increase compared to the pre-heparin level (p<0.00001). The administration of heparin also resulted in a marked fall in the level of thromboxane B2 in the blood shed from the site of the bleeding time determination. Paired data were obtained in 32 patients; their results are shown in Table 1 and Figure 2 . The mean shed blood thromboxane B2 prior to heparin was 11.5 ng/ml. Post heparin, it fell to 5.4 ng/ml (p = 0.00002). There was a moderate but significant correlation between Khuri 8 the bleeding time and the shed blood thromboxane B2 (r=0.43, p< 0.0005).
There were no significant negative correlations between the skin temperature and the changes in the corrected bleeding time and the shed blood thromboxane B2
level. Therefore, the changes in bleeding time and thromboxane B2 were not due to the slight fall in skin temperature that was observed between the pre*-arid postheparin time points.
von Willebrand Factor antigen concentration was measured before and 5 minutes after heparin administration in 15 patients. As shown in Table 1 , the vWF antigen concentration before and after heparin were not significantly different.
The vWF multimer distribution was not altered in patients after infusion of heparin, as measured by visual inspection of vWF antigen on autoradiographs ( Figure 3 ).
Fibrinolytic Activity: Table 2 Table 2 , the administration of heparin elicited no significant changes in the plasma levels of fibrinogen, tissue plasminogen activator, plasminogen, antiplasmin, and antithrombin III.
DISCUSSION
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This study demonstrates that, in patients undergoing open heart surgery, the administration of heparin, prior to the institution of cardiopulmonary bypass, causes platelet dysfunction (manifested by a prolongation of the bleeding time and a reduction in the ability of the platelet to produce thromboxane A2 in vivo) and increased fibrinolysis (manifested by increased plasma levels of plasmin and D-dimer). Hence, heparin contributes to the hemostatic defect observed in patients undergoing cardiac surgery not only by inhibiting coagulation through its effect on antithrombin HI, but also by eliciting direct adverse effects on the platelet and the fibrinolytic system.
Platelet dysfunction in open heart surgery and the effect of heparin
It has been long recognized that patients undergoing cardiac surgery have increased postoperative bleeding. This has been attributed to a cardiopulmonary bypass-induced hemostatic defect which was thought to be due mostly to platelet dysfunction and, to a lesser extent, increased fibrinolysis (1,10). Since the magnitude of thrombocytopenia encountered in the course of cardiac surgery is not severe enough to account for the marked extension of the bleeding time observed during and following cardiopulmonary bypass (2), investigations in this field have focused on specific platelet abnormalities that might be induced by cardiopulmonary bypass. The platelet defect of cardiopulmonary bypass has been postulated to be due to a loss of the platelet membrane receptors responsible for platelet adhesion and aggregation. Loss of platelet membrane receptors for both the vWF and fibrinogen were reported during and following cardiopulmonary bypass (11) (12) (13) . However, the methods with which the platelets were prepared in these studies involved centrifugation and gel filtration of the platelets prior to assay, thereby introducing the possibility of an artifactual in vitro decrease in platelet surface GPIb-IX complex (the vWF Khuri 10 receptor) and GPEb-IIIa complex (the fibrinogen receptor) as a result of proteolysis or activation.
In a study of 20 patients undergoing cardiac surgery, we utilized a flow cytometric method that allowed us to study the platelet GPIb-IX and GPHb/IIIa in whole blood, thereby avoiding potential artefactual reductions in platelet surface glycoprotein receptors. With thislnethod, we demonstrated that cardiopulmonary bypass did not result in a decrease in the platelet surface expression of neither the GPIb-IX complex nor the GPHb-DIa complex (3). This study underscored the possibility of factors extrinsic to the platelet itself that might contribute to the platelet dysfunction observed in patients undergoing cardiac surgery. Two such factors are hypothermia and heparin. In a study of 37 patients undergoing cardiopulmonary bypass, we confirmed the adverse effect of hypothermia on platelet function by demonstrating that hypothermia resulted in a significant prolongation of the bleeding time and a significant reduction in the ability of the platelet to produce thromboxane A2 (4).
Platelet function in the present study was-assessed by the measurement of the bleeding time and the level of thromboxane B 2 in the blood shed from the skin at the site of the bleeding time determination. Despite its limitations, the bleeding time continues to be a reliable indicator of platelet function and platelet-vessel wall interaction (1) . The measurement of the shed blood thromboxane B 2 has also been shown to be a reliable indicator of platelet function (2, 14) . It has the distinct advantage of reflecting in-vivo platelet function, making it an ideal measurement for use in patients undergoing cardiopulmonary bypass (2, 3, 4) . Both measurements indicated a marked reduction in platelet function following the administration of heparin. Although it has been long recognized that heparin caused a prolongation of the bleeding time (15) , its recognition as an etiologic factor in postbypass hemorrhage is only recent (1,16).
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The mechanism with which heparin might cause platelet dysfunction was partially addressed in our previous study in which whole blood flow cytometry was employed in the characterization of the platelet membrane glycoproteins lb and Ilb-HIa and platelet activation before and following cardiopulmonary bypass (3). That study provided evidence thäT heparin suppressed platelet activation in vivo via inhibition of endogenous thrombin, the latter being the most important platelet agonist in vivo.
Another possible mechanism for the inhibition of platelet function by heparin is through an inhibition of von Willebrand factor activity. Ristocetin is a cationic antibiotic which induces in vitro binding of vWF to its receptor on platelet GPlb. Sobel et al demonstrated that the intravenous administration of heparin to patients before open heart surgery reduced ristocetin cofactor activity by 58% (17) . This impairment of vWF-dependent platelet function was closely related to plasma heparin levels but not to plasma vWF levels. It appeared to be caused by direct binding of heparin to vWF in solution, but may also be a consequence of heparin binding directly to the platelet surface (18) . In the present study, we have demonstrated that the concentration and multimer distribution of the VWF were unaffected by the administration of heparin. Hence our data is consistent with the hypothesis that heparin reduces platelet function by preventing the vWF from binding to its receptor on the GPlb on the platelet.
The third mechanism by which heparin can induce platelet dysfunction is through its effect on plasmin. This is explained in the section below.
Fibrinolysis during cardiopulmonary bypass and the effect of heparin
There are a number of pathways that could lead to increased fibrinolysis during cardiopulmonary bypass surgery, including the activation of kallikrein and the release of t-PA Khuri 12 from the endothelial cell (1). Fibrin(ogen) degradation products (FDP) and D-dimer increase during and following cardiopulmonary bypass (1, 19) . Administration of aprotinin during cardiöpulmonary bypass prevents the formation of FDP and the reduction in o^-antiplasmin activity (20) . It also reduces the bleeding time (21) . These observations, the mechäTtfsnnjf action of aprotinin (22), and the clinical effectiveness of aprotinin in decreasing blood loss (21) finding of this mechanism is the significant correlation which was observed in this study between the bleeding time and the plasma levels of plasmin.
Clinical implications
The hemostatic defect observed in patients undergoing cardiac surgery is not fully reversed with the administration of protamine and the discontinuation of cardiopulmonary bypass.
In fact, D-dimer levels increase after the administration of protamine, and the bleeding time continues to be significantly elevated in the hours following the discontinuation of cardiopulmonary bypass (1,2). The bleeding time at two hours following cardiopulmonary bypass was shown to be an important determinant of postoperative blood loss (2) . Interventions aimed at reducing postoperative platelet dysfunction and fibrinolysis are likely to reduce postoperative blood loss in patients undergoing cardiac surgery. Because a variety of complex factors can potentially contribute to the hemostatic defect observed in the initial postoperative hours in these patients, it is very difficult to appreciate the specific contribution of the administration of heparin per se to this defect. Nevertheless, the present study raises questions as to whether an alternative anticoagulant or a lower dose of heparin might improve the hemostatic balance during open heart surgery. In the present study, the ACT was kept on the high side to achieve full suppression of thrombin. Significantly lower ACT levels have been employed in conjunction with heparin-coated Khuri 14 surfaces. It remains to be determined whether combining low-dose heparin with heparin-coated surfaces would suppress thrombin adequately and, at the same time, reduce the adverse effect of heparin on platelet function and fibrinolysis. It also remains to be determined whether an alternative anticoagulant that would not interfere with either the platelet function ortherfibrinolytic process can improve post-operative hemostasis in the cardiac surgical patient. 
